SCHEMBL311405

SCHEMBL311405

O=c1cc(-c2ccc(O)cc2)oc2ccc(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
NPC1 O15118 4/20 1.00
RAB9A P51151 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
CYP3A4 P08684 4/20 1.00
HPGD P15428 4/20 1.00
TP53 P04637 3/20 1.00
IP6K2 Q9UHH9 2/20 1.00
LMNA P02545 1/20 1.00
THRB P10828 1/20 1.00
ALOX15 P16050 1/20 1.00
CASP3 P42574 1/20 1.00
SENP8 Q96LD8 1/20 1.00
SENP7 Q9BQF6 1/20 1.00
SENP6 Q9GZR1 1/20 1.00
CSNK2A2 P19784 6/20 0.82
CSNK2B P67870 6/20 0.82
CSNK2A1 P68400 6/20 0.82
LCK P06239 2/20 0.82
CALM1 P0DP23 2/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31741263 1.00 MAPT (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL29374176 0.91 LCK (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL10305788 0.91 CSNK2A2 (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL31238426 0.91 MAPT (0.94) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL3644507 0.91 LCK (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
6-Hydroxyflavone SCHEMBL29628861 0.90 MAPT (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
6-Hydroxyflavone SCHEMBL676594 0.90 MAPT (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL31238388 0.88 MAPT (0.78) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL311326 0.88 MAPT (0.78) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL10144252 0.87 APP (1.00) MAPTNPC1RAB9ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119604294-A ERbeta estrogenic compounds and methods of use 益特瑞恩公司 2025-03-11 CN claimed
EP-3808348-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) Biogen MA Inc. (US) 2021-04-21 EP claimed
US-20130183289-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) BIOGEN IDEC MA INC (US) 2013-07-18 US claimed
EP-2200611-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) Biogen Idec MA, Inc. (US) 2010-06-30 EP claimed
WO-2009038684-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) BIOGEN IDEC MA INC. (US) 2009-03-26 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
WO-2003026705-A1 METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS CLEARANT, INC. (US) 2003-04-03 WO claimed
US-20030059338-A1 Methods for sterilizing biological materials using flavonoid/flavonol stabilizers CLEARANT, INC. 2003-03-27 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2026-04-30 US disclosed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
EP-4593631-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME Mars, Incorporated (US) 2025-08-06 EP disclosed
US-20250195452-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. 2025-06-19 US disclosed
US-20030059338-A1 Methods for sterilizing biological materials using flavonoid/flavonol stabilizers CLEARANT, INC. 2003-03-27 US disclosed
US-20030012687-A1 Methods of sterilizing biological materials CLEARANT, INC. 2003-01-16 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
US-6258856-B1 ADMINISTERING ESTROGEN FOR CATARACT PREVENTION THE UNIVERSITY OF SYDNEY (AU) 2001-07-10 US disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195452-A1 ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE ESR2, ESR1, ESRRB MAPT 1471/4885NPC1 1013/4885RAB9A 3011/4885
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME PIGS, TAS2R13, CEL MAPT 2113/4885NPC1 740/4885RAB9A 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.